Article Text

Download PDFPDF
Association of a polymorphism of the transforming growth factor-β1 gene with cerebral amyloid angiopathy
  1. T Hamaguchi1,
  2. S Okino1,
  3. N Sodeyama2,
  4. Y Itoh3,
  5. A Takahashi4,
  6. E Otomo3,
  7. M Matsushita5,
  8. H Mizusawa2,
  9. M Yamada1
  1. 1Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
  2. 2Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Tokyo, Japan
  3. 3Department of Internal Medicine, Yokufukai Geriatric Hospital, Tokyo, Japan
  4. 4Organ and Function Pathology Division, Yokufukai Geriatric Hospital, Tokyo, Japan
  5. 5Department of Neuropathology, Tokyo Institute of Psychiatry, Tokyo, Japan
  1. Correspondence to:
 Professor Masahito Yamada
 Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science, 13-1, Takara-machi, Kanazawa 920-8640, Japan; m-yamadamed.kanazawa-u.ac.jp

Abstract

Background: A recent study showed that transforming growth factor-β1 (TGF-β1) induces amyloid-β deposition in cerebral blood vessels and meninges of a transgenic mouse model of Alzheimer’s disease (AD), and that TGF-β1 mRNA levels are correlated with cerebral amyloid angiopathy (CAA) in human AD brains. A T/C polymorphism at codon 10 in exon 1 of the TGF-β1 gene has been reported to be associated with the serum TGF-β1 concentration. We investigated whether the TGF-β1 polymorphism is associated with the risk of CAA.

Methods: The association between the severity of CAA and the T/C polymorphism at codon 10 in exon 1 of the TGF-β1 was investigated in 167 elderly Japanese autopsy cases, including 73 patients with AD. The apolipoprotein E (APOE) genotype was also determined.

Results: The genotypes (TT/ TC/ CC) were associated with the severity of CAA significantly in all patients (p  =  0.0026), in non-AD patients (p  =  0.011), and APOE non-ε4 carriers (p  =  0.0099), but not in AD patients or APOE ε4 carriers. The number of the T alleles positively correlated with the severity of CAA in all patients (p  =  0.0011), non-AD patients (p  =  0.0026), and APOE non-ε4 carriers (p  =  0.0028), but not in AD patients or APOE ε4 carriers. The polymorphism was not significantly associated with AD.

Conclusions: Our results suggest that the polymorphism in TGF-β1 is associated with the severity of CAA, especially in non-AD patients and APOE non-ε4 carriers.

  • Aβ, amyloid β protein
  • AD, Alzheimer’s disease
  • APOE, apolipoprotein E
  • CAA, cerebral amyloid angiopathy
  • hAPP, human β-amyloid precursor protein
  • PCR, polymerase chain reaction
  • TGF-β1, transforming growth factor-β1
  • transforming growth factor β1
  • cerebral amyloid angiopathy
  • polymorphism

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Competing interests: none declared